SUBSCRIBE
SUBSCRIBE

Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology.

With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders.

For more information, please visit: www.daiichisankyo.com.

Daiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is a member of the Daiichi Sankyo Group. To learn more about Daiichi Sankyo, Inc., please visit www.dsi.com.

  • 2025 BPTW Badge - RBG.png
  • 2024 - Best Places to Work - Badges - Brighspot Rework - Outlined - 20pt.png
211 Mt. Airy Road
Basking Ridge, NJ 07920
Tel: (908) 992-6400
Visit website
  • Featured Employer
NEWS
FDA signage at its office in Maryland
Drug Development
FDA Action Alert: Verrica, Citius and Daiichi Sankyo
After beginning July with a splash in the Alzheimer’s space, the FDA is expected to make three decisions during the next two weeks; two for cancer and one for a viral skin disease.
July 13, 2023
 · 
4 min read
 · 
Tristan Manalac
AstraZeneca's sign on its office in California
Drug Development
AstraZeneca’s Phase III Lung Cancer Data Underwhelms Investors
Topline results for its Daiichi Sankyo-partnered antibody-drug conjugate showed statistically significant improvement. However, AstraZeneca shares dropped around 6% in early Monday trading.
July 3, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: 3D illustration of antibody-drug conjugates carrying toxic payloads
Drug Development
Antibody-Drug Conjugates, Lung Cancer Late-Breaker to Take Center Stage at ASCO
ADCs from BioNTech, Daiichi Sankyo and Merck are the subject of high-profile abstracts featured at the oncology meeting, along with Merck’s late-breaking Phase III non-small cell lung cancer data.
June 2, 2023
 · 
5 min read
 · 
Greg Slabodkin
Pictured: FDA Headquarters/Courtesy of Grandbrothe
FDA
FDA Delays Verdict for Daiichi Sankyo’s Quizartinib
To give the FDA more time to evaluate updates to quizartinib’s proposed REMS program, the regulator is pushing the target action date to July 24.
April 24, 2023
 · 
2 min read
 · 
Tristan Manalac
Courtesy of Daiichi Sankyo
Drug Development
Esperion-Daiichi Sankyo Partnership Saga Continues with Payment Spat
For Daiichi Sankyo, recent results from the Phase III CLEAR trial of Esperion Therapeutics’ Nexletol (bempedoic acid) were not convincing enough to trigger a milestone payment.
March 17, 2023
 · 
2 min read
 · 
Tristan Manalac
Business
Movers & Shakers: Odyssey, Daiichi Sankyo, Atsena and More
While Biogen and Seagen made the biggest C-suite splashes this week, other companies across the biopharma industry also bolstered their leadership teams with new talent.
November 10, 2022
 · 
6 min read
 · 
Alex Keown
Courtesy of Daiichi Sankyo
Drug Development
Daiichi Sankyo’s Ezharmia Becomes First EZH1/2 Inhibitor for Blood Cancer
Daiichi Sankyo won approval in Japan for Ezharmia, making it the first dual inhibitor of EZH1 and EZH2 to receive regulatory approval for ATL.
September 26, 2022
 · 
2 min read
 · 
Alex Keown
Biotech Bay
Remote Work Opportunities Abound at Pfizer, GRAIL, Regeneron and More
In a recent BioSpace poll, more than half of employers indicated they planned to continue recruiting employees remotely. We highlight just some of those jobs here.
September 21, 2022
 · 
5 min read
 · 
Lisa Munger
Mohammed Haneefa Nizamudeen_Getty Images
Drug Development
In Group of Firsts, ESMO Highlights Therapeutic Advances in Lung Cancer
NSCLC At ESMO: Pollution does indeed cause lung cancer; Tecentriq shows promise in poor prognosis patients, Amgen makes progress in KRAS G12-mutated disease and an update on a Daiichi Sankyo ADC.
September 14, 2022
 · 
6 min read
 · 
Gail Dutton
Load More
JOBS
View All Jobs at Daiichi Sankyo
IN THE PRESS
Drug Development
Datopotamab deruxtecan plus IMFINZI® (durvalumab) demonstrated robust and durable tumor responses in 1st-line treatment of patients with metastatic triple-negative breast cancer in BEGONIA Phase Ib/II trial
October 22, 2023
 · 
31 min read
Pharm Country
Raludotatug Deruxtecan Continues to Demonstrate Promising Clinical Activity in Patients with Advanced Ovarian Cancer in Early Trial
October 22, 2023
 · 
9 min read
Drug Development
Datopotamab Deruxtecan Plus Durvalumab Demonstrated Robust and Durable Tumor Responses in First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer in BEGONIA Phase 1b/2 Trial
October 22, 2023
 · 
10 min read
Business
Daiichi Sankyo and Merck Announce Global Development and Commercialization Collaboration for Three Daiichi Sankyo DXd ADCs
October 19, 2023
 · 
10 min read
Pharm Country
Daiichi Sankyo Showcases Progress in Developing New Standards of Care for Patients with Industry-Leading DXd ADC Portfolio Across Multiple Cancers at ESMO
October 16, 2023
 · 
9 min read
Business
Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial
September 22, 2023
 · 
9 min read
Drug Development
Datopotamab Deruxtecan Demonstrated Statistically Significant and Clinically Meaningful Progression-Free Survival Benefit in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial
September 22, 2023
 · 
7 min read
Business
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2-mutant Advanced Lung Cancer in DESTINY-Lung02 Phase II Trial
September 11, 2023
 · 
29 min read
Drug Development
ENHERTU® Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2 Mutant Advanced Lung Cancer in DESTINY-Lung02 Phase 2 Trial
September 11, 2023
 · 
30 min read
Drug Development
Datopotamab Deruxtecan Plus Durvalumab Showed Promising Clinical Activity in the First-Line Advanced Non-Small Cell Lung Cancer Setting in TROPION-Lung04 Phase 1b Trial
September 10, 2023
 · 
11 min read
Load More